Revenue

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue

REVENUE

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
Net product sales	$	11,308	$	10,798
Alliance revenues	188		142
Other revenues	152		133
Total Revenues	$	11,648	$	11,073

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
Gross product sales	$	16,650	$	15,559
GTN adjustments(a)
Charge-backs and cash discounts	(1,763)		(1,586)
Medicaid and Medicare rebates	(2,084)		(1,718)
Other rebates, returns, discounts and adjustments	(1,495)		(1,457)
Total GTN adjustments	(5,342)		(4,761)
Net product sales	$	11,308	$	10,798

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $74 million and $217 million for the three months ended March 31, 2022, and 2021, respectively.

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
In-Line Products
Eliquis	$	3,211	$	2,886
Opdivo	1,923		1,720
Pomalyst/Imnovid	826		773
Orencia	792		758
Sprycel	483		470
Yervoy	515		456
Empliciti	75		85
Mature and other products	462		506
New Product Portfolio
Reblozyl	156		112
Abecma	67		—
Zeposia	36		18
Breyanzi	44		—
Inrebic	18		16
Onureg	23		15
Opdualag	6		—
Recent LOE Products(a)
Revlimid	2,797		2,944
Abraxane	214		314
Total Revenues	$	11,648	$	11,073
United States	$	7,694	$	7,010
Europe	2,413		2,553
Rest of the World	1,314		1,346
Other(b)	227		164
Total Revenues	$	11,648	$	11,073

(a)    Recent LOE Products includes products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $147 million and $284 million for the three months ended March 31, 2022 and 2021, respectively, consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties for out-licensing arrangements.